An in-depth update on what we know about HCV risk, symptoms, screening, outcomes, and treatment (including financial barriers).
Cholesterol guidelines may underestimate statin value; shifting from Ryan White CARE Act to Affordable Care Act coverage; HCV seroconversion and CD4 count suppression; HCV reinfection odds by risk group.
With Only 15% of Diagnosed HCV Patients Receiving Treatment, the Non-Profit I-MAK Hopes to Shift the National Conversation on Drug Pricing
The Initiative for Medicines, Access and Knowledge, Inc. (I-MAK) argues that the high price of hepatitis C cure medicines places them out of reach for most people.
With the approval this month of two drugs to treat hepatitis C in children, these often overlooked victims of the opioid epidemic have a better chance at a cure.
A letter from the Obama Administration tells states that Medicaid must allow more people to get costly drugs that can cure their hep C, sending a strong messages for HIV and other diseases with high cost meds.
The ongoing struggle to enable access to sofosbuvir globally at affordable prices continues with several new developments.
Who has the power to prescribe medications? In the ongoing struggle to cure the estimated 3.2 million people living with chronic hepatitis C virus (HCV) infection in the U.S., the answer may not be who you think.
Gilead has devised a strategy to extract maximum profits, suggests policy analyst Brook Baker. He urges us not to blame governments and force taxpayers to create more pharmaceutical wealth, and instead calls for action to ensure access for all at an ...
An international group of treatment activists interrupted a session at AIDS 2014 just as Gregg H. Alton, a top official at Gilead Sciences, was about to speak regarding the challenges of expanding global access to the new generation of hepatitis C dr...
HCV drugs are priced out of reach and out of control.
-- Michel Sidibé, UNAIDS
MELBOURNE, Australia -- Treatment activists at the 20th International AIDS Conference held a die-in to protest the exorbitant pricing of Sovaldi (sofosbuvir), Gilead...